rivaroxaban and Mucocutaneous-Lymph-Node-Syndrome

Giant or large coronary artery aneurysms (CAA) are rare in children, most often secondary to Kawasaki disease, and anticoagulation is recommended to prevent thromboembolism. There are no published pediatric reports on the use of a direct oral anticoagulant for this indication. We describe the anticoagulation management of an 8-year-old boy with a dilated right CAA secondary to Kawasaki disease that has remained stable on rivaroxaban and aspirin, following bleeding complications on enoxaparin and challenges on warfarin. The use of rivaroxaban appears to be safe and effective in the prevention of thrombosis in a pediatric patient with CAA.

Topics: Anticoagulants; Child; Coronary Aneurysm; Coronary Vessels; Humans; Male; Mucocutaneous Lymph Node Syndrome; Rivaroxaban; Venous Thromboembolism